Welcome to our dedicated page for INTENSITY THERAPEUTICS news (Ticker: INTS), a resource for investors and traders seeking the latest updates and insights on INTENSITY THERAPEUTICS stock.
Intensity Therapeutics, Inc. develops intratumoral cancer therapies using proprietary non-covalent drug-conjugation technology. Its lead investigational product candidate, INT230-6, is designed for direct injection into tumors and combines cisplatin, vinblastine sulfate, and the SHAO diffusion and cell-penetration enhancer to disperse cytotoxic agents within cancer cells.
Recurring company news covers INT230-6 clinical development, including the INVINCIBLE-4 study in early-stage operable triple negative breast cancer and the INVINCIBLE-3 study in selected soft tissue sarcoma subtypes. Updates also address financial results, cash resources, intellectual-property protection for the intratumoral technology platform, at-the-market financing activity, Nasdaq listing compliance, and capital-structure actions affecting the company’s common stock.
Intensity Therapeutics announced promising results from its phase 1/2 trial involving the cancer treatment INT230-6. Patients receiving INT230-6 alone had a median overall survival (mOS) of 373 days, significantly longer compared to historical data. In combination with pembrolizumab, the mOS was 205 days in a heavily pretreated patient group. The treatment has shown good tolerability and efficacy, inducing both tumor cell death and immune activation. Results will be presented at the SITC Annual Meeting, indicating ongoing research towards potential commercialization.
Intensity Therapeutics announced positive data from the INVINCIBLE study, showcasing significant tumor necrosis in early-stage breast cancers resistant to chemotherapy. The trial utilized INT230-6, which demonstrated up to 100% necrosis from a single injection, alongside increased immune cell activity in the tumor microenvironment. No surgical procedures were canceled or delayed due to the treatment. Results will be presented at the 2022 SITC Annual Meeting, indicating INT230-6's potential to alter treatment paradigms for patients awaiting surgery.